Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC — Stella

Home/Hepatocellular Carcinoma Non-resectable/

View on ClinicalTrials.gov

Recruiting

Back to Hepatocellular Carcinoma Non-resectable trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Large-scale testing

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Collaborators

Affiliated Hospital of Guangdong Medical University, Zhongshan People's Hospital, Guangdong, China

Enrollment target

~258 participants

Started

August 2023

Primary completion

July 2027

Age range

18 Years and older

Last updated August 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.